Many cancers still lack effective treatments, and traditional chemotherapy can cause significant systemic toxicity due to its non-specific targeting of both healthy and cancerous cells. This results in a need for more precise cancer therapies that can selectively target and destroy cancer cells while minimizing harm to normal tissues.

Emergence Bio develops antibody-drug conjugates (ADCs) designed to target specific cancer cells, thereby enhancing the precision and efficacy of cancer treatment. Their approach involves linking a potent cytotoxic drug to a monoclonal antibody that selectively binds to a specific antigen expressed on cancer cells. Once the ADC binds to the cancer cell, it is internalized, releasing the cytotoxic drug inside the cell and triggering cell death. This targeted delivery aims to improve treatment outcomes for cancers with high unmet medical needs by reducing systemic toxicity and increasing the therapeutic effect on malignant cells.

Utilizes monoclonal antibodies to selectively target antigens on cancer cells.

Employs potent cytotoxic drugs as payloads to induce cancer cell death upon internalization.

ADC design minimizes off-target effects, reducing toxicity to healthy tissues.

Aims to improve treatment outcomes for aggressive malignancies with limited therapeutic options.

The primary target audience includes patients with cancers that express specific antigens amenable to ADC therapy, as well as oncologists seeking more effective and less toxic treatment options for their patients.